Ben Haynor: Well, yes I mean, I know historically or at least at points historically, you’ve mentioned that the product forecast is that Zimmer has given you that – maybe been increasingly favorable or aggressive, I don’t know, in the right way to characterize it. But just kind of getting at – trying to get what their outlook is, has that changed any positively or negatively? And then does that change – what activities you have to undertake on the manufacturing side?
Dave Rosa: Well, I think you always have to be concerned with your supply chain being able to meet, not just demand or the forecast that you have, but beyond that. So that we’ve been spending a lot of time with our supply chain to make sure that they can exceed what we’re doing. So in terms of Zimmer and their attitude, I think Zimmer has always been excited about this technology from the time we signed the contract a few years ago. I mean this is the technology that’s really synergistic with their robot. And they remain at least in all the discussions, I have with them just as excited to get going as we are. So, I would say there’s really no change. I think there’s been this pent-up excitement that all of us been waiting for over the last year and hopefully in the next couple of months, we’ll be able to start the show.
Ben Haynor: And then you mentioned a couple of months you’ve got AANS meeting coming up here. Are there any activities you planned around the U.S. sEEG electrode that you’ve been privy to with the Zimmer launch or at that show or anything special plan that you can share?
Dave Rosa: Yes, I don’t know what the plans are for that show outside of exhibiting. I think we also have to be careful especially when you’re doing a controlled launch that you don’t go out and try to bring too many sites on at one time. So as I said earlier, it’s going to be a very controlled methodical launch, where we walk before we run just to make sure everything’s performing the way we need it to, and make sure that we have the product supply that we need when there’s a full launch, but nothing that I’m aware of yet.
Ben Haynor: Okay, no problem. And then a couple on the kind of R&D project, you’re going to submit OneRF in a couple of months here it sounds like it. What’s going to be beyond the V&V and – the additional animal testing there?
Dave Rosa: Yes, I mean, it’s really documentation beyond that and it’s not trivial. So we’ve completed, let’s just say, we’ve gone through the heavy lifting. I mean, I’m not trying to minimize the amount of testing that has to be done, because it’s not trivial. But once we got the design behind us and the development behind us and some of these additional feasibility studies. I mean, we feel really good about the technology and where we’re at that, we will be able to submit sometime early in Q2. Now that’s barring anything unforeseen in this DB testing. I mean, there’s always something that could come up. But so far, I mean, last few months, we’ve been doing of testing with the system and are really encouraged with the performance.
Ben Haynor: Okay, great. And then on the drug delivery device that can stimulate and record, is that something that you could actually generate some near-term revenue for drug trials and such for research use only applications. I know you mentioned you plan a preclinical study, but how quickly could there be revenue associated with that device?
